Next Science Limited (NXSCF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -15.05 Million | -11.78 Million | -8.26 Million | -11.9 Million | -12.33 Million |
| Net Income | - | - | - | - | - |
| Depreciation & Amortization | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | - | - | - | - | - |
| Other non-cash items | - | - | - | - | - |
| Investing Cash Flow | -884.5 Thousand | -475.71 Thousand | -716.75 Thousand | -686.79 Thousand | -1.6 Million |
| Investments in PPE | -884.46 Thousand | -475.71 Thousand | -716.75 Thousand | -686.79 Thousand | -1.6 Million |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -34.00 | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | -589.05 Thousand | - | - | - | - |
| Financing Cash Flow | 20.1 Million | 10.24 Million | 1.42 Million | 10.71 Million | 23.68 Million |
| Debt repayment | - | - | - | - | -70.79 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | -637.86 Thousand | -385.63 Thousand | -6230.00 | -387.74 Thousand | -1.71 Million |
| Common Stock Issuance | 21.01 Million | 10.88 Million | 1.64 Million | 11.32 Million | 25.54 Million |
| Other Financing Activities | -273.27 Thousand | -253.22 Thousand | -212.75 Thousand | -222.6 Thousand | 72.85 Thousand |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | - | - | - | - | - |
| Cash at beginning of period | 5.07 Million | 7.36 Million | 15.33 Million | 16.91 Million | 7.21 Million |
| Cash at end of period | 9.23 Million | 5.11 Million | 7.36 Million | 15.33 Million | 16.91 Million |
| Capital Expenditure | -884.46 Thousand | -475.71 Thousand | -716.75 Thousand | -686.79 Thousand | -1.6 Million |
| Effect of forex changes on cash | 935.00 | -238.39 Thousand | -417.07 Thousand | 312.18 Thousand | -45.25 Thousand |
| Net cash flow / Change in cash | 4.16 Million | -2.25 Million | -7.97 Million | -1.57 Million | 9.69 Million |
| Free Cash Flow | -15.94 Million | -12.26 Million | -8.98 Million | -12.59 Million | -13.93 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.92 Million | -2.92 Million | -7.98 Million | - | -3.82 Million | -8.49 Million |
| Depreciation & Amortization | 618.91 Thousand | - | 607.2 Thousand | - | 368.98 Thousand | 523.55 Thousand |
| Deferred income taxes | - | - | -538.57 Thousand | - | - | - |
| Stock-based compensation | - | - | 67.21 Thousand | - | 67.21 Thousand | - |
| Change in working capital | - | - | -743.05 Thousand | - | -743.05 Thousand | - |
| Other non-cash items | 402.6 Thousand | 402.6 Thousand | 764.19 Thousand | - | 515.66 Thousand | 1.3 Million |
| Investing Cash Flow | -164.37 Thousand | -164.37 Thousand | -405.2 Thousand | -884.5 Thousand | -185.39 Thousand | -506.44 Thousand |
| Investments in PPE | -5823.00 | -5823.00 | -405.16 Thousand | -884.46 Thousand | -19.08 Thousand | -506.44 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -35.48 | -34.00 | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -158.55 Thousand | -158.55 Thousand | -166.31 Thousand | - | -166.31 Thousand | -128.22 Thousand |
| Financing Cash Flow | -59.97 Thousand | -59.97 Thousand | 14.15 Million | 20.1 Million | 6.66 Million | 6.67 Million |
| Debt repayment | - | - | - | - | - | -6.88 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | -637.86 Thousand | - | - |
| Common Stock Issuance | - | - | 21.32 Million | 21.01 Million | - | -61.75 Thousand |
| Other Financing Activities | -59.97 Thousand | -59.97 Thousand | 6.66 Million | -273.27 Thousand | 6.66 Million | 3.38 Million |
| Accounts receivables | - | - | -954.64 Thousand | - | -954.64 Thousand | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | 136.52 Thousand | - | 136.52 Thousand | - |
| Other working capital | - | - | 75.05 Thousand | - | 75.05 Thousand | - |
| Cash at beginning of period | 9.21 Million | - | 3.48 Million | 5.07 Million | - | 5.09 Million |
| Cash at end of period | 3.56 Million | -2.83 Million | 9.21 Million | 9.23 Million | 2.87 Million | 3.48 Million |
| Capital Expenditure | -5823.00 | -5823.00 | -405.16 Thousand | -884.46 Thousand | -19.08 Thousand | -506.44 Thousand |
| Effect of forex changes on cash | -90.43 Thousand | -90.43 Thousand | 14.2 Thousand | 935.00 | 14.2 Thousand | -13.73 Thousand |
| Net cash flow / Change in cash | -5.65 Million | -2.83 Million | 5.73 Million | 4.16 Million | 2.87 Million | -1.61 Million |
| Free Cash Flow | -2.52 Million | -2.52 Million | -8.23 Million | -15.94 Million | -3.63 Million | -8.21 Million |
AYMSYNTEX
VAPIENTER
300562
ARTZF
0204
ISGIF